JP2020517698A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517698A5
JP2020517698A5 JP2019558390A JP2019558390A JP2020517698A5 JP 2020517698 A5 JP2020517698 A5 JP 2020517698A5 JP 2019558390 A JP2019558390 A JP 2019558390A JP 2019558390 A JP2019558390 A JP 2019558390A JP 2020517698 A5 JP2020517698 A5 JP 2020517698A5
Authority
JP
Japan
Prior art keywords
pyrido
pyrimidin
amine
pyridine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019558390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517698A (ja
JP7247102B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/052919 external-priority patent/WO2018198077A2/en
Publication of JP2020517698A publication Critical patent/JP2020517698A/ja
Publication of JP2020517698A5 publication Critical patent/JP2020517698A5/ja
Priority to JP2022144957A priority Critical patent/JP2022188056A/ja
Application granted granted Critical
Publication of JP7247102B2 publication Critical patent/JP7247102B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019558390A 2017-04-28 2018-04-26 6-6縮合二環式ヘテロアリール化合物及びlats阻害剤としてのその使用 Active JP7247102B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022144957A JP2022188056A (ja) 2017-04-28 2022-09-13 6-6縮合二環式ヘテロアリール化合物及びlats阻害剤としてのその使用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762491526P 2017-04-28 2017-04-28
US201762491475P 2017-04-28 2017-04-28
US201762491484P 2017-04-28 2017-04-28
US201762491573P 2017-04-28 2017-04-28
US62/491,475 2017-04-28
US62/491,526 2017-04-28
US62/491,573 2017-04-28
US62/491,484 2017-04-28
US201862650232P 2018-03-29 2018-03-29
US62/650,232 2018-03-29
PCT/IB2018/052919 WO2018198077A2 (en) 2017-04-28 2018-04-26 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022144957A Division JP2022188056A (ja) 2017-04-28 2022-09-13 6-6縮合二環式ヘテロアリール化合物及びlats阻害剤としてのその使用

Publications (3)

Publication Number Publication Date
JP2020517698A JP2020517698A (ja) 2020-06-18
JP2020517698A5 true JP2020517698A5 (https=) 2021-06-10
JP7247102B2 JP7247102B2 (ja) 2023-03-28

Family

ID=62148436

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019558390A Active JP7247102B2 (ja) 2017-04-28 2018-04-26 6-6縮合二環式ヘテロアリール化合物及びlats阻害剤としてのその使用
JP2022144957A Pending JP2022188056A (ja) 2017-04-28 2022-09-13 6-6縮合二環式ヘテロアリール化合物及びlats阻害剤としてのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022144957A Pending JP2022188056A (ja) 2017-04-28 2022-09-13 6-6縮合二環式ヘテロアリール化合物及びlats阻害剤としてのその使用

Country Status (25)

Country Link
US (2) US11458138B2 (https=)
EP (1) EP3615537B1 (https=)
JP (2) JP7247102B2 (https=)
KR (1) KR20190142776A (https=)
CN (3) CN114703144A (https=)
AU (2) AU2018260495B2 (https=)
BR (1) BR112019022512A2 (https=)
CA (1) CA3056906A1 (https=)
CL (1) CL2019003049A1 (https=)
CO (1) CO2019011873A2 (https=)
CR (1) CR20190483A (https=)
CU (2) CU20200080A7 (https=)
DO (1) DOP2019000273A (https=)
EC (1) ECSP19076732A (https=)
ES (1) ES2983611T3 (https=)
IL (2) IL269293B (https=)
JO (1) JOP20190257A1 (https=)
MA (1) MA49285A (https=)
MX (1) MX2019012756A (https=)
PE (1) PE20200292A1 (https=)
PH (1) PH12019502436A1 (https=)
SG (1) SG11201908615RA (https=)
TW (1) TW201843140A (https=)
UY (1) UY37703A (https=)
WO (1) WO2018198077A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
KR102483020B1 (ko) 2016-03-28 2023-01-04 인사이트 코포레이션 Tam 저해제로서의 피롤로트리아진 화합물
WO2018175636A2 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
MA50655B1 (fr) 2017-09-27 2021-11-30 Incyte Corp Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam
TW202005643A (zh) 2018-06-08 2020-02-01 日商日產化學股份有限公司 激酶抑制劑
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
EP3866730A4 (en) * 2018-10-16 2022-07-06 The Schepens Eye Research Institute, Inc. BIOADHESIVE FOR SOFT TISSUE REPAIR
UY38427A (es) * 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
WO2020122104A1 (ja) 2018-12-11 2020-06-18 国立大学法人京都大学 ゲノムdnaに欠失を誘導する方法
CN113348017A (zh) 2019-01-30 2021-09-03 日产化学株式会社 酰肼化合物及激酶抑制剂
CN112707905B (zh) * 2019-10-25 2024-07-02 武汉誉祥医药科技有限公司 一种三并杂环化合物及其制备方法和用途
GB201915831D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
JP7759877B2 (ja) * 2019-11-27 2025-10-24 ジェネンテック, インコーポレイテッド 治療用化合物
CA3170121A1 (en) 2020-02-05 2021-08-12 The Rockefeller University Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss
CN111443068B (zh) * 2020-03-06 2023-06-27 天津大学 具有多重刺激响应特性的纯有机室温磷光材料及筛选方法和应用
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
JP2023522784A (ja) 2020-04-27 2023-05-31 ノバルティス アーゲー 眼細胞療法のための方法及び組成物
KR20230007441A (ko) * 2020-04-28 2023-01-12 글로벌 블러드 테라퓨틱스, 인크. 페로포르틴 억제제로서의 시클로알킬 피리미딘
CN112305126A (zh) * 2020-11-02 2021-02-02 宁夏贝利特生物科技有限公司 一种硝酸胍含量的测定方法
KR20240016977A (ko) * 2021-06-04 2024-02-06 제넨테크, 인크. 2,8-디아자스피로[4.5]데칸 화합물
WO2023027978A1 (en) * 2021-08-23 2023-03-02 Emd Millipore Corporation System and method for photopolymerizing electrophoretic gels
CN115974868B (zh) * 2022-11-07 2024-04-12 安徽理工大学 一种尿嘧啶衍生物的合成方法及其抗肺纤维化方面的潜在应用
WO2024211621A1 (en) * 2023-04-04 2024-10-10 Children's Hospital Los Angeles Lats kinase inhibitor to treat retinal degeneration
CN119462609B (zh) * 2024-10-25 2025-12-26 烟台皓元生物医药科技有限公司 一种lats抑制剂vt02956的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065392A1 (en) 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
JP2008531538A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド 2,4−ジアミノ−ピリドピリミジン誘導体とmTOR阻害剤としてのその使用
EP2144908A1 (en) 2007-04-06 2010-01-20 Novartis Ag 2, 6-naphthyridine derivatives as protein kinase modulators
CA2729045A1 (en) 2008-07-31 2010-02-04 Philippe Bergeron Pyrimidine compounds, compositions and methods of use
US20110319409A1 (en) * 2010-06-23 2011-12-29 Cox Christopher D 7-aza-quinazoline pde10 inhibitors
JP5761827B2 (ja) 2011-07-15 2015-08-12 国立大学法人大阪大学 角膜内皮細胞の調製方法
EP2760857A1 (en) 2011-09-27 2014-08-06 F.Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
KR102215272B1 (ko) * 2012-09-28 2021-02-15 이그니타, 인코포레이티드 비정형 단백질 키나제 c의 아자퀴나졸린 억제제
JP7103750B2 (ja) * 2013-12-12 2022-07-20 ザ・ブロード・インスティテュート・インコーポレイテッド ゲノム編集のためのCRISPR-Cas系及び組成物の送達、使用及び治療適用
TWI675836B (zh) 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶c之氮雜喹唑啉抑制劑
EP3197557A1 (en) 2014-09-24 2017-08-02 Friedrich Miescher Institute for Biomedical Research Lats and breast cancer
EA033686B1 (ru) 2015-08-03 2019-11-15 Bristol Myers Squibb Co Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа
EP3341079A4 (en) 2015-08-25 2019-05-08 President and Fellows of Harvard College METHOD AND COMPOSITIONS RELATED TO DIAGNOSIS AND TREATMENT OF CANCER
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
UY38427A (es) * 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares

Similar Documents

Publication Publication Date Title
JP2020517698A5 (https=)
US20230190751A1 (en) 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors
KR102635333B1 (ko) Pd-1/pd-l1 억제제
CN104136444B (zh) Fgf受体(fgfr)激动剂二聚化合物、及其制备方法和治疗用途
JP2015518843A (ja) 創傷、例えば、糖尿病性創傷の処置における、dpp−4阻害剤と組み合わせてもよい生物活性物質としてのケラチン生成細胞の使用
ES2659980T3 (es) Agente para promover la adherencia de células endoteliales de la córnea
Parker et al. Hydrogel for simultaneous tunable growth factor delivery and enhanced viability of encapsulated cells in vitro
RU2015117536A (ru) Vegf-нейтрализирующие пролекарства для лечения офтальмологических заболеваний
CA3116512A1 (en) Methods and compositions for ocular cell therapy
JP2018502900A (ja) ジスコイジンドメイン受容体1を標的化する小分子阻害剤およびその使用
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
AU2018361971A1 (en) Compounds and use thereof in the expansion of stem cells and/or progenitor cells
CN110402141A (zh) Axl抑制剂和EGFR酪氨酸激酶抑制剂的联合疗法
CA3154084A1 (en) Feeder-based and feeder-free stem cell culture systems for stratified epithelial stem cells, and uses related thereto
RU2022117596A (ru) 6-6-конденсированные бициклические гетероарильные соединения и их применение в качестве ингибиторов lats
RU2775721C2 (ru) 6-6-конденсированные бициклические гетероарильные соединения и их применение в качестве ингибиторов lats
EA038453B1 (ru) 6-6-конденсированные бициклические гетероарильные соединения и их применение в качестве ингибиторов lats
US20250376466A1 (en) Ester compounds and use thereof
US20250243251A1 (en) Compositions and methods for targeting mxra8 to treat obesity and associated metabolic diseases
JP2014108930A (ja) 抗がん剤